Temozolomide Accord 140 mg hard capsules.

DRUG3 trials

Sponsors

Institut De Recherches Internationales Servier IRIS, Helse Bergen HF, Universitair Medisch Centrum Utrecht

Conditions

Diffuse Midline GliomaGrade IV recurrent glioma which includes both glioblastomaH3K27-alteredIDH1-mutant GliomaIDH2-mutant Gliomaclassified as IDH wt and grade IV IDH mutated astrocytoma.

Phase 1

BORTEZOMIB SENSITIZATION OF RECURRENT GRADE-4 GLIOMA WITH UNMETHYLATED MGMT PROMOTER TO TEMOZOLOMIDE. PHASE IB/II. (BORTEM 17)

RecruitingCTIS2024-515142-16-00

Helse Bergen HFclassified as IDH wt and grade IV IDH mutated astrocytoma., Grade IV recurrent glioma which includes both glioblastoma

Start: 2024-10-03Target: 63Updated: 2024-10-02

A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma

Active, not recruitingCTIS2024-513738-39-00

Institut De Recherches Internationales Servier IRISIDH1-mutant Glioma, IDH2-mutant Glioma

Start: 2025-03-18Target: 17Updated: 2025-12-18

FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial

Not yet recruitingCTIS2025-520814-78-00

Universitair Medisch Centrum UtrechtDiffuse Midline Glioma, H3K27-altered

Target: 20Updated: 2026-03-23